Jasper Therapeutics, Inc.
NCM: JSPRLive Quote
About Jasper Therapeutics, Inc.
Healthcare
Biotechnology
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
📊 Fundamental Analysis
Jasper Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -230.3%, which indicates that capital utilization is currently under pressure.
At a current price of $0.80, JSPR currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $0.62 - $7.19).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$13.05M
Trailing P/E
--
Forward P/E
-0.48
Beta (5Y)
3.20
52W High
$7.19
52W Low
$0.62
Avg Volume
503K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App